HR Breast Cancer
Advertisement
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
The study used SEER data of nearly 20,000 cases.
People diagnosed with metastatic breast cancer have a notably increased risk of developing heart disease.
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease.
New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.
The Breast Cancer Index assists in decision-making regarding adjuvant endocrine therapy for hormone receptor-positive BC.
Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer.
Dr. Margaret Gatti-Mays details the treatment options for BC patients in the hormone receptor-positive metastatic setting.
The Oncology Brothers spoke with Dr. Margaret Gatti-Mays, who provided invaluable insights on hormone receptor-positive BC.
Patients ≥70 years of age were more likely to have a reduction in their palbociclib dosage.
The FDA recently approved a new combination therapy for the treatment of HR-positive, HER2-negative breast cancer.
The Oncology Brothers talk with Paolo Tarantino, MD, about the TROPiCS-02 study presented at SABCS.
Results from the 21-gene Breast Recurrence Score commercial assay were successful predictors for cancer-specific mortality.
The Oncology Brothers were live at ASCO 2023 to discuss findings from the TROPiCS-02 study.
Sacituzumab govitecan wasn't cost-effective in HR+/HER2- metastatic breast cancer for third-party payers in the US.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.